Cargando…
Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351319/ https://www.ncbi.nlm.nih.gov/pubmed/26836226 http://dx.doi.org/10.1111/cts.12386 |
| _version_ | 1782514754565177344 |
|---|---|
| author | Venkatakrishnan, K Burgess, C Gupta, N Suri, A Takubo, T Zhou, X DeMuria, D Lehnert, M Takeyama, K Singhvi, S Milton, A |
| author_facet | Venkatakrishnan, K Burgess, C Gupta, N Suri, A Takubo, T Zhou, X DeMuria, D Lehnert, M Takeyama, K Singhvi, S Milton, A |
| author_sort | Venkatakrishnan, K |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5351319 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-53513192017-05-23 Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles Venkatakrishnan, K Burgess, C Gupta, N Suri, A Takubo, T Zhou, X DeMuria, D Lehnert, M Takeyama, K Singhvi, S Milton, A Clin Transl Sci Research John Wiley and Sons Inc. 2016-02-05 2016-02 /pmc/articles/PMC5351319/ /pubmed/26836226 http://dx.doi.org/10.1111/cts.12386 Text en © 2016 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Research Venkatakrishnan, K Burgess, C Gupta, N Suri, A Takubo, T Zhou, X DeMuria, D Lehnert, M Takeyama, K Singhvi, S Milton, A Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles |
| title | Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles |
| title_full | Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles |
| title_fullStr | Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles |
| title_full_unstemmed | Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles |
| title_short | Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles |
| title_sort | toward optimum benefit‐risk and reduced access lag for cancer drugs in asia: a global development framework guided by clinical pharmacology principles |
| topic | Research |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351319/ https://www.ncbi.nlm.nih.gov/pubmed/26836226 http://dx.doi.org/10.1111/cts.12386 |
| work_keys_str_mv | AT venkatakrishnank towardoptimumbenefitriskandreducedaccesslagforcancerdrugsinasiaaglobaldevelopmentframeworkguidedbyclinicalpharmacologyprinciples AT burgessc towardoptimumbenefitriskandreducedaccesslagforcancerdrugsinasiaaglobaldevelopmentframeworkguidedbyclinicalpharmacologyprinciples AT guptan towardoptimumbenefitriskandreducedaccesslagforcancerdrugsinasiaaglobaldevelopmentframeworkguidedbyclinicalpharmacologyprinciples AT suria towardoptimumbenefitriskandreducedaccesslagforcancerdrugsinasiaaglobaldevelopmentframeworkguidedbyclinicalpharmacologyprinciples AT takubot towardoptimumbenefitriskandreducedaccesslagforcancerdrugsinasiaaglobaldevelopmentframeworkguidedbyclinicalpharmacologyprinciples AT zhoux towardoptimumbenefitriskandreducedaccesslagforcancerdrugsinasiaaglobaldevelopmentframeworkguidedbyclinicalpharmacologyprinciples AT demuriad towardoptimumbenefitriskandreducedaccesslagforcancerdrugsinasiaaglobaldevelopmentframeworkguidedbyclinicalpharmacologyprinciples AT lehnertm towardoptimumbenefitriskandreducedaccesslagforcancerdrugsinasiaaglobaldevelopmentframeworkguidedbyclinicalpharmacologyprinciples AT takeyamak towardoptimumbenefitriskandreducedaccesslagforcancerdrugsinasiaaglobaldevelopmentframeworkguidedbyclinicalpharmacologyprinciples AT singhvis towardoptimumbenefitriskandreducedaccesslagforcancerdrugsinasiaaglobaldevelopmentframeworkguidedbyclinicalpharmacologyprinciples AT miltona towardoptimumbenefitriskandreducedaccesslagforcancerdrugsinasiaaglobaldevelopmentframeworkguidedbyclinicalpharmacologyprinciples |